Bath Savings Trust Co Cuts Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Bath Savings Trust Co trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 21,814 shares of the company’s stock after selling 157 shares during the quarter. Bath Savings Trust Co’s holdings in IDEXX Laboratories were worth $11,021,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of IDXX. Ossiam boosted its holdings in shares of IDEXX Laboratories by 17.4% in the 4th quarter. Ossiam now owns 3,753 shares of the company’s stock worth $2,083,000 after buying an additional 557 shares during the last quarter. Lighthouse Investment Partners LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at approximately $2,688,000. Putnam Investments LLC raised its holdings in shares of IDEXX Laboratories by 3.1% in the 4th quarter. Putnam Investments LLC now owns 189,978 shares of the company’s stock worth $105,447,000 after purchasing an additional 5,624 shares during the period. Nebula Research & Development LLC bought a new position in IDEXX Laboratories during the fourth quarter valued at $1,562,000. Finally, Point72 Asset Management L.P. purchased a new stake in IDEXX Laboratories in the fourth quarter worth $78,001,000. 87.84% of the stock is currently owned by institutional investors.

IDEXX Laboratories Stock Performance

NASDAQ IDXX opened at $472.41 on Tuesday. The company has a market capitalization of $39.01 billion, a P/E ratio of 45.73, a P/E/G ratio of 4.32 and a beta of 1.33. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39. The company has a fifty day moving average of $487.95 and a 200-day moving average of $495.66.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing the consensus estimate of $2.88 by ($0.44). The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.01 billion. IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. IDEXX Laboratories’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter last year, the company posted $2.67 earnings per share. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 10.45 EPS for the current fiscal year.

Analyst Ratings Changes

IDXX has been the subject of several recent research reports. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. Piper Sandler dropped their price target on shares of IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 14th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. Finally, BTIG Research assumed coverage on IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 target price for the company. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $582.25.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.